THOUSAND OAKS, Calif. - Biotechnology manufacturer Amgen formally enacted strict compliance rules on Nov. 15 requiring covered healthcare entities to submit detailed patient encounter records to receive federal drug discounts.
Healthcare Providers Must Submit Clinical Visit Records
Beginning Nov. 15, hospitals and community health centers seeking statutory discounts under the federal 340B Drug Pricing Program must transmit clinical visit records through the central 340B ESP reporting portal. "Starting November 15, 2026, covered entities that want Amgen's 340B pricing must also submit standard healthcare visit and service claims data for their 340B pharmacy and medical claims of Amgen drugs, through the 340B ESP platform," healthcare regulatory analysts confirmed. Pharmacy dispense claims require submission within forty-five days, while clinic-administered medications must be reported within sixty days.
Health Center Advocates Warn of Heavy Operational Burdens
The National Association of Community Health Centers filed formal administrative petitions urging the Health Resources and Services Administration to halt Amgen's unilateral data requirements. Clinic administrators emphasized that standard electronic health record architectures and pharmacy billing platforms do not automatically link prescription dispensing records with rendering physician identifiers and primary diagnostic coding. Industry representatives warned that diverting limited operational resources toward complex data reconciliations threatens to compromise subsidized medical care for medically underserved rural populations.
Mandatory Corporate Requirements Clash With Federal Pilot Standards
Amgen's commercial policy establishes a significant precedent, marking the first time a pharmaceutical manufacturer has mandated encounter-level clinical data as a condition for statutory product pricing. The requirement conflicts directly with the federal government's planned 340B rebate pilot program scheduled for launch in January 2027, which explicitly prohibits drugmakers from requiring patient visit datasets. While twelve states maintain state-level legal exemptions for local contract pharmacies, national hospital associations are preparing comprehensive legal challenges against corporate eligibility restrictions.


